Summary

The results of the Japanese Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by Atrial Natriuretic Peptide (ANP) or Nicorandil [J-WIND] trials conducted in Japan from 2001–2006. Carperitide, human recombinant ANP, is approved for the treatment of acute heart failure in Japan. Nicorandil, a nicotinamide nitrate that activates potassium channels in the heart, is used to treat chronic angina. These randomized, double-blind studies evaluated intervention with either carperitide or nicorandil on infarct size, left ventricular function, and associated outcomes.